

Thomas Gruenberger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3674536/publications.pdf>

Version: 2024-02-01

147
papers

14,740
citations

46918

47
h-index

18606

119
g-index

151
all docs

151
docs citations

151
times ranked

13259
citing authors

#	ARTICLE	IF	CITATIONS
1	ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. <i>Annals of Oncology</i> , 2016, 27, 1386-1422.	0.6	2,545
2	Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. <i>Lancet</i> , The, 2008, 371, 1007-1016.	6.3	1,759
3	Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study. <i>CardioVascular and Interventional Radiology</i> , 2010, 33, 41-52.	0.9	1,329
4	Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 1208-1215.	5.1	1,017
5	Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. <i>Lancet Oncology</i> , The, 2010, 11, 38-47.	5.1	873
6	Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2016, 27, v28-v37.	0.6	523
7	Bevacizumab, Capecitabine, and Oxaliplatin As Neoadjuvant Therapy for Patients With Potentially Curable Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 1830-1835.	0.8	403
8	Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. <i>Annals of Oncology</i> , 2009, 20, 985-992.	0.6	310
9	Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. <i>Annals of Oncology</i> , 2015, 26, 702-708.	0.6	271
10	Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. <i>European Journal of Cancer</i> , 2007, 43, 2037-2045.	1.3	249
11	Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. <i>Lancet Oncology</i> , The, 2010, 11, 1142-1148.	5.1	220
12	Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). <i>Annals of Oncology</i> , 2014, 25, 1018-1025.	0.6	213
13	Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983. <i>European Journal of Cancer</i> , 2014, 50, 912-919.	1.3	190
14	Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. <i>European Journal of Surgical Oncology</i> , 2009, 35, 515-520.	0.5	147
15	Urgent Need for a New Staging System in Advanced Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 4828-4833.	0.8	146
16	Influence of Hepatic Resection Margin on Recurrence and Survival in Intrahepatic Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2008, 15, 2787-2794.	0.7	142
17	Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 3314-3324.	0.8	139
18	Liver Resection for Colorectal Metastases in Presence of Extrahepatic Disease: Results from an International Multi-institutional Analysis. <i>Annals of Surgical Oncology</i> , 2011, 18, 1380-1388.	0.7	138

#	ARTICLE	IF	CITATIONS
19	Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. <i>Annals of Oncology</i> , 2004, 15, 478-483.	0.6	129
20	Sinusoidal Obstruction Syndrome Impairs Long-Term Outcome of Colorectal Liver Metastases Treated with Resection after Neoadjuvant Chemotherapy. <i>Annals of Surgical Oncology</i> , 2011, 18, 421-430.	0.7	120
21	Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases. <i>BMC Cancer</i> , 2008, 8, 120.	1.1	109
22	Bevacizumab Improves Pathological Response of Colorectal Cancer Liver Metastases Treated with XELOX/FOLFOX. <i>Annals of Surgical Oncology</i> , 2010, 17, 2059-2065.	0.7	104
23	Size of surgical margin does not influence recurrence rates after curative liver resection for colorectal cancer liver metastases. <i>British Journal of Surgery</i> , 2007, 94, 1133-1138.	0.1	100
24	HER 2/neu protein expression in colorectal cancer. <i>BMC Cancer</i> , 2006, 6, 123.	1.1	97
25	Immunomodulatory effects of glycine on LPS-treated monocytes: reduced TNF α production and accelerated IL-10 expression. <i>FASEB Journal</i> , 1999, 13, 563-571.	0.2	95
26	The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008. <i>Annals of Oncology</i> , 2009, 20, vii1-vii6.	0.6	94
27	Predictive Factors for the Benefit of Perioperative FOLFOX for Resectable Liver Metastasis in Colorectal Cancer Patients (EORTC Intergroup Trial 40983). <i>Annals of Surgery</i> , 2012, 255, 534-539.	2.1	91
28	Preoperative evaluation of colorectal liver metastases: comparison between gadoxetic acid-enhanced 3.0-T MRI and contrast-enhanced MDCT with histopathological correlation. <i>European Radiology</i> , 2013, 23, 2187-2196.	2.3	91
29	Evidence for serotonin as a relevant inducer of liver regeneration after liver resection in humans. <i>Hepatology</i> , 2014, 60, 257-266.	3.6	91
30	Activated Mammalian Target of Rapamycin Is an Adverse Prognostic Factor in Patients with Biliary Tract Adenocarcinoma. <i>Clinical Cancer Research</i> , 2007, 13, 4795-4799.	3.2	87
31	B Cells and Ectopic Follicular Structures: Novel Players in Anti-Tumor Programming with Prognostic Power for Patients with Metastatic Colorectal Cancer. <i>PLoS ONE</i> , 2014, 9, e99008.	1.1	86
32	Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases. <i>European Journal of Surgical Oncology</i> , 2008, 34, 1231-1236.	0.5	80
33	Preoperative detection of colorectal liver metastases in fatty liver: MDCT or MRI?. <i>European Journal of Radiology</i> , 2011, 79, e1-e6.	1.2	79
34	Liver Failure after Major Liver Resection: Risk Assessment by Using Preoperative Gadoxetic Acid-enhanced 3-T MR Imaging. <i>Radiology</i> , 2013, 269, 777-786.	3.6	77
35	Gadoxetic acid-enhanced 3.0-T MR imaging versus multidetector-row CT in the detection of colorectal metastases in fatty liver using intraoperative ultrasound and histopathology as a standard of reference. <i>European Journal of Surgical Oncology</i> , 2012, 38, 670-676.	0.5	76
36	Lymph node ratio after curative surgery for intrahepatic cholangiocarcinoma. <i>British Journal of Surgery</i> , 2009, 96, 919-925.	0.1	72

#	ARTICLE	IF	CITATIONS
37	Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983. <i>European Journal of Cancer</i> , 2015, 51, 2708-2717.	1.3	72
38	KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab. <i>British Journal of Surgery</i> , 2012, 99, 1575-1582.	0.1	69
39	Progression while Receiving Preoperative Chemotherapy Should Not Be an Absolute Contraindication to Liver Resection for Colorectal Metastases. <i>Annals of Surgical Oncology</i> , 2012, 19, 2786-2796.	0.7	69
40	Circulating Free Methylated Tumor DNA Markers for Sensitive Assessment of Tumor Burden and Early Response Monitoring in Patients Receiving Systemic Chemotherapy for Colorectal Cancer Liver Metastasis. <i>Annals of Surgery</i> , 2018, 268, 894-902.	2.1	69
41	The profile of platelet granule released molecules affects postoperative liver regeneration. <i>Hepatology</i> , 2016, 63, 1675-1688.	3.6	67
42	Treatment and outcome of intrahepatic cholangiocellular carcinoma. <i>American Journal of Surgery</i> , 2005, 189, 173-177.	0.9	64
43	It is possible to omit postoperative irradiation in a highly selected group of elderly breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 1998, 50, 37-46.	1.1	59
44	Long-term outcomes of patients with 10 or more colorectal liver metastases. <i>British Journal of Cancer</i> , 2017, 117, 604-611.	2.9	58
45	Thrombospondin-1: a unique marker to identify in vitro platelet activation when monitoring in vivo processes. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 1809-1819.	1.9	52
46	The impact of liver transplantation on endocrine status in men. <i>Clinical Endocrinology</i> , 1996, 44, 461-466.	1.2	51
47	Evaluation of Chemotherapy-Associated Liver Injury in Patients with Colorectal Cancer Liver Metastases Using Indocyanine Green Clearance Testing. <i>Annals of Surgical Oncology</i> , 2011, 18, 1644-1650.	0.7	49
48	Soluble Axl is an accurate biomarker of cirrhosis and hepatocellular carcinoma development: results from a large scale multicenter analysis. <i>Oncotarget</i> , 2017, 8, 46234-46248.	0.8	49
49	Post-treatment imaging of liver tumours. <i>Cancer Imaging</i> , 2007, 7, S28-S36.	1.2	48
50	Long-term follow-up of surgically treated gallbladder cancer patients. <i>European Journal of Surgical Oncology</i> , 2002, 28, 857-863.	0.5	47
51	Reduction in Recurrence Risk for Involved or Inadequate Margins With Edge Cryotherapy After Liver Resection for Colorectal Metastases. <i>Archives of Surgery</i> , 2001, 136, 1154.	2.3	46
52	Value of hepatic venous pressure gradient measurement before liver resection for hepatocellular carcinoma. <i>British Journal of Surgery</i> , 2011, 98, 1752-1758.	0.1	45
53	Side effects during chemotherapy predict tumour response in advanced colorectal cancer. <i>British Journal of Cancer</i> , 2005, 93, 744-748.	2.9	43
54	Bivalent role of intra-platelet serotonin in liver regeneration and tumor recurrence in humans. <i>Journal of Hepatology</i> , 2017, 67, 1243-1252.	1.8	43

#	ARTICLE	IF	CITATIONS
55	Nitrous oxide may not increase the risk of cancer recurrence after colorectal surgery: a follow-up of a randomized controlled trial. <i>BMC Anesthesiology</i> , 2009, 9, 1.	0.7	42
56	Liver Resection Remains a Safe Procedure After Neoadjuvant Chemotherapy Including Bevacizumab. <i>Annals of Surgery</i> , 2010, 252, 124-130.	2.1	42
57	Pathologic response to bevacizumab-containing chemotherapy in patients with colorectal liver metastases and its correlation with survival. <i>Surgical Oncology</i> , 2012, 21, 309-315.	0.8	42
58	Resection of colorectal liver metastases after second-line chemotherapy: is it worthwhile? A LiverMetSurvey analysis of 6415 patients. <i>European Journal of Cancer</i> , 2017, 78, 7-15.	1.3	42
59	Intermediate Monocytes but Not TIE2-Expressing Monocytes Are a Sensitive Diagnostic Indicator for Colorectal Cancer. <i>PLoS ONE</i> , 2012, 7, e44450.	1.1	41
60	Multicenter analysis of soluble α 1 reveals diagnostic value for very early stage hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2015, 137, 385-394.	2.3	41
61	Perioperative Non-Invasive Indocyanine Green-Clearance Testing to Predict Postoperative Outcome after Liver Resection. <i>PLoS ONE</i> , 2016, 11, e0165481.	1.1	40
62	The VEGF rise in blood of bevacizumab patients is not based on tumor escape but a host-blockade of VEGF clearance. <i>Oncotarget</i> , 2016, 7, 57197-57212.	0.8	40
63	Perioperative von Willebrand factor dynamics are associated with liver regeneration and predict outcome after liver resection. <i>Hepatology</i> , 2018, 67, 1516-1530.	3.6	39
64	Multicenter validation study of pathologic response and tumor thickness at the tumor-normal liver interface as independent predictors of disease-free survival after preoperative chemotherapy and surgery for colorectal liver metastases. <i>Cancer</i> , 2013, 119, 2778-2788.	2.0	38
65	Andrological Status Before and After Liver Transplantation. <i>Journal of Urology</i> , 1994, 151, 1251-1254.	0.2	37
66	Colorectal Liver Metastasis in the Setting of Lymph Node Metastasis: Defining the Benefit of Surgical Resection. <i>Annals of Surgical Oncology</i> , 2012, 19, 435-442.	0.7	37
67	Adequate preoperative staging rarely leads to a change of intraoperative strategy in patients undergoing surgery for colorectal cancer liver metastases. <i>Surgery</i> , 2008, 143, 648-657.	1.0	36
68	PARAGON II – A single arm multicentre phase II study of neoadjuvant therapy using irinotecan bead in patients with resectable liver metastases from colorectal cancer. <i>European Journal of Surgical Oncology</i> , 2016, 42, 1866-1872.	0.5	35
69	Neoadjuvant Therapy With Bevacizumab. <i>Journal of Clinical Oncology</i> , 2006, 24, 2592-2593.	0.8	34
70	Predicting Postoperative Liver Dysfunction Based on Blood-Derived MicroRNA Signatures. <i>Hepatology</i> , 2019, 69, 2636-2651.	3.6	33
71	Selective resection of colorectal liver metastases. <i>European Journal of Surgical Oncology</i> , 2007, 33, 174-182.	0.5	31
72	Immune phenotype and histopathological growth pattern in patients with colorectal liver metastases. <i>British Journal of Cancer</i> , 2020, 122, 1518-1524.	2.9	31

#	ARTICLE	IF	CITATIONS
73	Neoadjuvant Treatment of Colorectal Cancer with Bevacizumab: The Perioperative Angiogenic Balance Is Sensitive to Systemic Thrombospondin-1 Levels. <i>Clinical Cancer Research</i> , 2008, 14, 2065-2074.	3.2	29
74	Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 1547-1556.	1.9	28
75	EORTC liver metastases intergroup randomized phase III study 40983: Long-term survival results.. <i>Journal of Clinical Oncology</i> , 2012, 30, 3508-3508.	0.8	27
76	The Combination of APRI and ALBI Facilitates Preoperative Risk Stratification for Patients Undergoing Liver Surgery After Neoadjuvant Chemotherapy. <i>Annals of Surgical Oncology</i> , 2019, 26, 791-799.	0.7	25
77	HB-EGF is a paracrine growth stimulator for early tumor prestages in inflammation-associated hepatocarcinogenesis. <i>Journal of Hepatology</i> , 2008, 49, 955-964.	1.8	23
78	Neoadjuvant bevacizumab persistently inactivates VEGF at the time of surgery despite preoperative cessation. <i>British Journal of Cancer</i> , 2012, 107, 961-966.	2.9	23
79	Segmental and lobar administration of drug-eluting beads delivering irinotecan leads to tumour destruction: a case-control series. <i>Hpb</i> , 2013, 15, 71-77.	0.1	23
80	Assessing the TP53 marker type in patients treated with or without neoadjuvant chemotherapy for resectable colorectal liver metastases: A p53 Research Group study. <i>European Journal of Surgical Oncology</i> , 2015, 41, 683-689.	0.5	23
81	Plasma thrombospondin 1 as a predictor of postoperative liver dysfunction. <i>British Journal of Surgery</i> , 2015, 102, 826-836.	0.1	23
82	Resection of Hilar Cholangiocarcinomas: Pivotal Prognostic Factors and Impact of Tumor Sclerosis. <i>World Journal of Surgery</i> , 2003, 27, 680-684.	0.8	22
83	Clinical relevance of molecular diagnostics in gastrointestinal (GI) cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 17th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona. <i>European Journal of Cancer</i> , 2017, 86, 305-317.	1.3	22
84	Shanghai international consensus on diagnosis and comprehensive treatment of colorectal liver metastases (version 2019). <i>European Journal of Surgical Oncology</i> , 2020, 46, 955-966.	0.5	22
85	Surgery after neoadjuvant chemotherapy for colorectal liver metastases is safe and feasible in elderly patients. <i>Journal of Surgical Oncology</i> , 2009, 100, 364-371.	0.8	20
86	Monocytes with angiogenic potential are selectively induced by liver resection and accumulate near the site of liver regeneration. <i>BMC Immunology</i> , 2014, 15, 50.	0.9	20
87	Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases. <i>European Journal of Surgical Oncology</i> , 2015, 41, 868-874.	0.5	20
88	PARENCHYMAL LIVER INJURY IN ORTHOTOPIC LIVER TRANSPLANTATION ¹ . <i>Transplantation</i> , 2000, 69, 2079-2084.	0.5	19
89	Clinical evidence for thrombospondin-1 as a relevant suppressor of liver regeneration. <i>Journal of Hepatology</i> , 2013, 58, 1053-1054.	1.8	17
90	Echogenicity of Liver Metastases Is an Independent Prognostic Factor After Potentially Curative Treatment. <i>Archives of Surgery</i> , 2000, 135, 1285-1290.	2.3	16

#	ARTICLE	IF	CITATIONS
91	Hepatic steatosis assessment with 1H-spectroscopy and chemical shift imaging at 3.0T before hepatic surgery: Reliable enough for making clinical decisions?. <i>European Journal of Radiology</i> , 2012, 81, 2990-2995.	1.2	15
92	CEA Change After Neoadjuvant Chemotherapy Including Bevacizumab and Clinical Outcome in Patients Undergoing Liver Resection for Colorectal Liver Metastases. <i>Annals of Surgical Oncology</i> , 2015, 22, 1315-1323.	0.7	15
93	Treatment sequence of synchronously (liver) metastasized colon cancer. <i>Digestive and Liver Disease</i> , 2016, 48, 1119-1123.	0.4	15
94	Austrian Joint A-GGH-A-GIR-A-GHO-ASSO position statement on the use of transarterial chemoembolization (TACE) in hepatocellular carcinoma. <i>Wiener Klinische Wochenschrift</i> , 2012, 124, 104-110.	1.0	14
95	Early prediction of postoperative liver dysfunction and clinical outcome using antithrombin III-activity. <i>PLoS ONE</i> , 2017, 12, e0175359.	1.1	14
96	Late ureteral obstruction after kidney transplantation.. <i>Transplant International</i> , 1997, 10, 65-68.	0.8	13
97	The EGF 61A/G polymorphism â€“ a predictive marker for recurrence of liver metastases from colorectal cancer. <i>Wiener Klinische Wochenschrift</i> , 2009, 121, 638-643.	1.0	13
98	Variations in genes involved in immune response checkpoints and association with outcomes in patients with resected colorectal liver metastases. <i>Pharmacogenomics Journal</i> , 2015, 15, 521-529.	0.9	13
99	Chemotherapy of colorectal liver metastases induces a rapid rise in intermediate blood monocytes which predicts treatment response. <i>Oncolimmunology</i> , 2016, 5, e1160185.	2.1	13
100	Consequences of Perioperative Serotonin Reuptake Inhibitor Treatment During Hepatic Surgery. <i>Hepatology</i> , 2021, 73, 1956-1966.	3.6	13
101	Deficiency in Thrombopoietin Induction after Liver Surgery Is Associated with Postoperative Liver Dysfunction. <i>PLoS ONE</i> , 2015, 10, e0116985.	1.1	12
102	Genetic variations in angiopoietin and pericyte pathways and clinical outcome in patients with resected colorectal liver metastases. <i>Cancer</i> , 2015, 121, 1898-1905.	2.0	12
103	The Role of Biological Agents in the Resection of Colorectal Liver Metastases. <i>Clinical Oncology</i> , 2012, 24, 432-442.	0.6	11
104	Echogenicity of liver metastases from colorectal carcinoma is an independent prognostic factor in patients treated with regional chemotherapy. <i>Cancer</i> , 2002, 94, 1753-1759.	2.0	10
105	Synchronous liver metastases in patients with rectal cancer: can we establish which treatment first?. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591878799.	1.4	10
106	The 3-60 criteria challenge established predictors of postoperative mortality and enable timely therapeutic intervention after liver resection. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 111-124.	0.7	10
107	Preservation of the liver: is it possible to extend the time of storage?. <i>Transplantation Proceedings</i> , 1999, 31, 2074-2076.	0.3	9
108	Surgery for liver metastases originating from sarcomaâ€”case series. <i>Langenbeck's Archives of Surgery</i> , 2011, 396, 1083-1091.	0.8	9

#	ARTICLE	IF	CITATIONS
109	Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2814-2821.	1.9	9
110	Effects of continuous remifentanyl administration on intraoperative subcutaneous tissue oxygen tension. <i>Anaesthesia</i> , 2007, 62, 1101-1109.	1.8	8
111	Variations in genes involved in dormancy associated with outcome in patients with resected colorectal liver metastases. <i>Annals of Oncology</i> , 2015, 26, 1728-1733.	0.6	8
112	The Immune Phenotype of Isolated Lymphoid Structures in Non-Tumorous Colon Mucosa Encrypts the Information on Pathobiology of Metastatic Colorectal Cancer. <i>Cancers</i> , 2020, 12, 3117.	1.7	7
113	Elevated ADAMTS13 Activity is Associated with Poor Postoperative Outcome in Patients Undergoing Liver Resection. <i>Scientific Reports</i> , 2018, 8, 16823.	1.6	6
114	Immunological Aspects of AXL/GAS6 in the Context of Human Liver Regeneration. <i>Hepatology Communications</i> , 2022, 6, 576-592.	2.0	5
115	Role of platelets in systemic tissue protection after remote ischemic preconditioning. <i>Hepatology</i> , 2014, 60, 1136-1138.	3.6	4
116	Reply. <i>Hepatology</i> , 2015, 62, 984-984.	3.6	4
117	Building a collaboration to improve surgical research through EORTC/ESSO 1409-CLIMB study: A prospective liver metastasis database with an integrated quality assurance program. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1870-1875.	0.5	4
118	Circulating metabolites as a concept beyond tumor biology determining disease recurrence after resection of colorectal liver metastasis. <i>Hpb</i> , 2022, 24, 116-129.	0.1	4
119	Cetuximab and chemotherapy in the treatment of patients with initially "nonresectable" colorectal (CRC) liver metastases: Long-term follow-up of the CELIM trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 3538-3538.	0.8	4
120	Effect of Goal-Directed Crystalloid versus Colloid Administration on Perioperative Hemostasis in Partial Hepatectomy: A Randomized, Controlled Trial. <i>Journal of Clinical Medicine</i> , 2021, 10, 1651.	1.0	3
121	Neoadjuvant treatment of colorectal liver metastases (CRLM) with drug eluting beads trans-arterial chemoembolization (DEBIRI-TACE): A multi-institute phase II study in resectable metastases.. <i>Journal of Clinical Oncology</i> , 2012, 30, 3613-3613.	0.8	3
122	Interim follow up results from a phase II study of neoadjuvant chemoembolization of resectable colorectal liver metastases (CRLM) with transcatheter hepatic therapy with irinotecan-eluting beads.. <i>Journal of Clinical Oncology</i> , 2013, 31, 519-519.	0.8	3
123	Austrian Consensus on the surgical treatment of colorectal liver metastases. <i>Memo - Magazine of European Medical Oncology</i> , 2009, 2, 38-40.	0.3	2
124	Liver surgery for metastatic colorectal cancer: the surgical oncologist perspective. <i>Colorectal Cancer</i> , 2016, 5, 115-125.	0.8	2
125	First experiences with mesh wrapping for parenchymal liver injuries in orthotopic liver transplantation. <i>Transplantation Proceedings</i> , 1999, 31, 538-539.	0.3	1
126	Use of Absorbable Mesh in the Treatment of Parenchymal Liver Injuries during Orthotopic Liver Transplantation. <i>The European Journal of Surgery</i> , 2001, 167, 29-34.	1.0	1

#	ARTICLE	IF	CITATIONS
127	Staged Treatment of Bilobar Hepatic Metastases from Colorectal Cancer. The European Journal of Surgery, 2002, 168, 516-518.	1.0	1
128	Using bevacizumab and cetuximab before liver surgery. Current Colorectal Cancer Reports, 2008, 4, 126-129.	1.0	1
129	Surgery vs surgery and chemotherapy for colorectal liver metastases – Authors' reply. Lancet, The, 2008, 372, 203.	6.3	1
130	Systemic effects of anti-VEGF therapy – Mini-review. European Surgery - Acta Chirurgica Austriaca, 2010, 42, 12-16.	0.3	1
131	VEGF and EGFR inhibition: opening a new door to cancer treatment. European Surgery - Acta Chirurgica Austriaca, 2010, 42, 24-28.	0.3	1
132	The role of platelets and portal venous pressure fluctuations in postoperative liver regeneration. European Surgery - Acta Chirurgica Austriaca, 2015, 47, 312-318.	0.3	1
133	Reply. Hepatology, 2015, 62, 319-320.	3.6	1
134	EORTC-ESSO 1409 GITCG: A prospective colorectal liver metastasis database with an integrated quality assurance program (CLIMB).. Journal of Clinical Oncology, 2018, 36, 3558-3558.	0.8	1
135	Immunological risk factors are solely responsible for primary non-function of renal allografts. Transplant International, 1994, 7, 294-297.	0.8	0
136	Authors' reply: Size of surgical margin does not influence recurrence rates after curative liver resection for colorectal cancer liver metastases (<i>Br J Surg</i> 2007; 94: 1133–1138). British Journal of Surgery, 2007, 95, 129-129.	0.1	0
137	Criteria for resectability of colorectal cancer liver metastases – an Austrian survey and current recommendations. European Surgery - Acta Chirurgica Austriaca, 2009, 41, 213-220.	0.3	0
138	Colorectal Cancer Liver Metastases (CLM) – ASCO 2010. Memo - Magazine of European Medical Oncology, 2010, 3, 178-179.	0.3	0
139	Laparoscopic hepatectomy: an alternative to open surgery for colorectal liver metastases?. European Surgery - Acta Chirurgica Austriaca, 2012, 44, 164-167.	0.3	0
140	Clinical management of patients with complicated multifocal disease. Cancer Imaging, 2014, 14, .	1.2	0
141	Cure in metastatic disease: How to manage and who is the right patient in colorectal cancer?. Memo - Magazine of European Medical Oncology, 2018, 11, 317-321.	0.3	0
142	Colorectal Cancer Liver Metastases: Neoadjuvant Therapy with Bevacizumab. , 2009, , 439-444.		0
143	Association of marked thrombocytopenia at postoperative day 1 with incidence of liver dysfunction, morbidity, and mortality in metastatic colorectal cancer patients undergoing liver resection.. Journal of Clinical Oncology, 2012, 30, e14095-e14095.	0.8	0
144	Activity of neoadjuvant bevacizumab at the time of surgery after 6 weeks of preoperative cessation: A translational study.. Journal of Clinical Oncology, 2012, 30, e14099-e14099.	0.8	0

#	ARTICLE	IF	CITATIONS
145	Association outcome with genes involved in immune response and checkpoints in patients with resected colorectal liver metastases.. Journal of Clinical Oncology, 2014, 32, 3563-3563.	0.8	0
146	Association of outcome with genes involved in tumor dormancy in patients with resected colorectal liver metastases.. Journal of Clinical Oncology, 2014, 32, e14512-e14512.	0.8	0
147	Influence of genetic variations of the angiopoietin and pericyte pathways in resected colorectal liver metastases.. Journal of Clinical Oncology, 2014, 32, 3564-3564.	0.8	0